Patch/Stampede
Langley RE, Nankivell M, Gilbert D, Bourmpaki E, Mangar S, Rush HL, Rosen S, Alhasso A, Kockelbergh R, Marshall J, Griffiths A, Chan KHY, Mohamed WM, Dallas NL, Brown SJ, Clarke N, James N, Parmar M. LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer. Ann Oncol. 2024;35. S1258. DOI: 10.1016/j.annonc.2024.08.2312.
Gilbert DC, Nankivell M, Sehjal J, Rush H, Mangar S, Gale J, et al. A0474 – Androgen suppression, PSA response, toxicity and longer-term outcomes with transdermal oestradiol (tE2) patches compared with LHRH analogues for the treatment of locally advanced prostate cancer, the phase III PATCH (NCT00303784) and STAMPEDE (NCT00268476) trials. Conference presentation at: Annual European Association of Urology Congress; 2025 March 21-24; Madrid, Spain.
James ND, Rush H, Nankivell MG, Sehjal J, Mangar SA, McPhail N et al. 21 Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. J Clin Oncol. 2025;43(5 suppl), 21-21. DOI:10.1200/JCO.2025.43.5_suppl.21
Rush, H. L., Merrick, S., Marshall, J., Deighan, J., Abdel-Aty, H., Alhasso, A., Clarke, N. W., Kockelbergh, R., Mangar, S., Rosen, S. D., James, N. D., Gilbert, D. C., South, A., & Langley, R. E. (2025, July 30). Preferences between three options for androgen deprivation therapy: A focus group study. BJU International. https://doi.org/10.1111/bju.16863
To learn more about the PATCH trial in the United Kingdom, visit:
http://patch.mrcctu.ucl.ac.uk
Not Related to Patch/Stampede
McNamara, D. (2025, September 3). Hormone therapy type key to memory benefits after menopause. Medscape Medical News. https://www.medscape.com/viewarticle/hormone-therapy-type-key-memory-benefits-after-menopause-2025a1000nat
Gambacciani, M., & Simoncini, T. (2025). From sex hormone decrease to hormonal treatment: Impacts on cardiovascular risk with ageing. Cardiovascular Research, cvaf086. https://doi.org/10.1093/cvr/cvaf086
Rabin, R. C. (2025, July 21). F.D.A. panelists call for removal of warnings on menopause treatments. The New York Times. https://www.nytimes.com/2025/07/17/health/hormone-therapy-menopause-fda.html